Institutional Equity Research for Undercovered Public Companies
Alliance Equity Research publishes independent and company-sponsored research on undercovered, emerging, and high-potential public companies globally.
Search AER-covered companies and Insights, or explore listed companies across supported global markets.
Latest Research
Recent initiation reports, research updates and company commentary from Alliance Equity Research.
ASML Holding N.V.
ASML
A Near-Monopoly Lithography Franchise Powering Global Semiconductor Supply Chain with EUV Dominance and High-NA Optionality
Initiation coverage examining EUV leadership, High-NA optionality, DUV economics, installed-base services, competitive moat, semiconductor demand drivers, valuation summary, and key risks.
Dexcom, Inc.
DXCM
Dominant CGM Franchise Leveraging Technology, Coverage Expansion, and Consumer Tailwinds to Sustain Multi-Year Growth
Initiation coverage examining CGM market leadership, product strategy, reimbursement expansion, recurring sensor economics, international growth, valuation summary, and key risks.
Insights
Timely analysis of company developments, industry trends, capital markets activity, and emerging investment themes across global public markets.
Mining & Critical MineralsIvanhoe’s Copper Recovery Gains Support From Acid Sales and Solar Power
Kamoa-Kakula’s latest operating update shows how local acid demand and a changing power supply can influence copper margins. Understanding the benefit requires following the project from underground ore through processing, sales and the costs of its continuing recovery.
Special SituationsExail’s Thales Takeover Brings Its Earlier Acquisition Financing Back Into Focus
Exail’s revised accounts bring obligations from its 2022 expansion into focus as Thales pursues a €134-per-share takeover. Its maritime robotics and navigation businesses are growing, while settlement rights held by ICG and employees add complexity to the acquisition’s financial structure.
Mining & Critical MineralsCaledonia’s Lower Gold Guidance Still Requires a Sharp Fourth-Quarter Recovery at Blanket
Caledonia has reduced its 2026 production outlook and raised unit-cost guidance after equipment and processing problems at Blanket. The revised target still assumes a fourth-quarter recovery, while deferred capital expenditure provides near-term cash relief without reducing the underlying investment requirement.
Biotechnology & HealthcareViatris’s Pacira Deal Buys Established Pain Medicines, but Growth Must Justify the Price
Viatris’s $1.65 billion cash offer adds two marketed non-opioid pain medicines and a U.S. commercial platform. The investment case depends on product durability, international expansion and cash returns, with Pacira’s debt, recent divestiture and adjusted earnings complicating a simple acquisition-multiple comparison.
Technology & SemiconductorsWolfspeed’s $1.5 Billion Government Loan Comes With a $750 Million Capital Test
The conditional 30-year facility could replace high-cost first-lien debt and fund U.S. silicon carbide and gallium nitride capacity. Yet no loan has closed, later draws require commercial milestones, and Wolfspeed must provide at least $750 million of qualifying capital while issuing warrants.
Technology & SemiconductorsXanadu’s GlobalFoundries Partnership Moves Quantum Computing Toward Manufacturing, With Economics Still Unproven
A 300 mm foundry partnership addresses the production of photonic chips and detectors needed for Xanadu’s planned quantum systems. The investment case now depends on translating component performance into manufacturing yields, integrated demonstrators and commercially useful machines while controlling development spending.
EnergyEnergy Transfer’s $2.6 Billion Vaquero Deal Buys Volumes for Its Wider Network
The acquisition adds contracted Delaware Basin gas-processing capacity already connected to Energy Transfer’s downstream infrastructure. Returns will depend on capturing additional transportation and export fees while funding a cash-heavy purchase alongside an expanding construction program.
Biotechnology & HealthcareVaxcyte’s Phase 3 Success Advances a Broader Vaccine Toward Its Next Regulatory Tests
VAX-31 passed every primary endpoint in its pivotal adult trial, supporting a broader pneumococcal vaccine profile. Individual comparator results, remaining manufacturing studies and rising development spending will shape the path to Vaxcyte’s planned 2028 filing and eventual commercial opportunity.
Explore Coverage
AER-covered companies combine public-company information with our proprietary research, updates, and commentary.
Find AER-Covered Companies
Explore AER-covered companies by sector, region, and market capitalization.
Research Built Around the Model
Alliance Equity Research develops written company analysis and detailed financial models together. The model is used to test operating assumptions, financial outcomes, scenarios, and valuation frameworks.
- Fundamental company analysis
- Integrated financial modeling
- Scenario-based valuation framework
- Ongoing coverage after initiation
Operating Drivers
RevenuePricingVolumeKPIsFinancial Forecast
Illustrative forecast structure, without financial values Metric FY1 FY2 FY3 FY4 Revenue Forecast output placeholder Forecast output placeholder Forecast output placeholder Forecast output placeholder EBITDA Forecast output placeholder Forecast output placeholder Forecast output placeholder Forecast output placeholder FCF Forecast output placeholder Forecast output placeholder Forecast output placeholder Forecast output placeholder Scenarios & Sensitivities
BaseUpsideDownsideValuation
DCF · Trading Multiples
Published Research
Is Your Company Undercovered?
Alliance Equity Research works with listed companies, recently listed companies, and businesses preparing to list, with a focus on undercovered, emerging, and high-potential opportunities. Our coverage includes initiation research, detailed financial modeling, and ongoing research updates.
- Initiation Research
- Financial Model
- Ongoing Updates
Investor Discovery
- AER Website
- AlphaSense
- FactSet
- Distribution Partners
Stay Current with AER
Choose the research and Insights updates you want to receive.